At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 6 enrolled
Drug / intervention
14C-APD421drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label, Single Dose, Single Period Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C] APD421 Administered Via the Intravenous Route to Healthy Male Subjects
In Brief
A Phase 1 clinical trial evaluating 14C-APD421 for Post-operative Nausea and Vomiting. Completed, enrolled 6 participants across 1 site.
Detailed Summary
Open-label, non-randomised, single dose study in 6 healthy male subjects to assess the mass balance recovery, metabolite profile, metabolite identification and pharmacokinetics of 14C-labelled APD421
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPost-operative Nausea and Vomiting
CountriesNetherlands
Collaborators--
Timeline
Phase 1CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartAug 2016
Primary CompletionAug 2016
First PostedAug 2016
TodayJul 2026
First PostedAug 29, 2016
Enrollment StartAug 1, 2016
Primary CompletionAug 1, 2016
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 9.8 years ago
Interventions
14C-APD421drug